Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 4, 2010, Pages 441-451

  Hirsch, Elizabeth B ^a,b   Tam, Vincent H ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b St Lukes Episcopal Hospital   (United States)

Author keywords

antipseudomonal agents; infection; morbidity; mortality; outcomes; resistance; virulence

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RNA METHYLTRANSFERASE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TICARCILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; DRUG COST; DRUG EFFICACY; DRUG TREATMENT FAILURE; ECONOMIC EVALUATION; HEALTH ECONOMICS; HOSPITALIZATION COST; HUMAN; INFECTION RISK; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; RISK FACTOR; THERAPY DELAY;

ANTI-INFECTIVE AGENTS; DRUG COSTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEALTH CARE COSTS; HUMANS; LENGTH OF STAY; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS; TREATMENT FAILURE; VIRULENCE;

EID: 77955779224     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.49     Document Type: Review

References (73)

1. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch. Intern. Med. 145(9), 1621-1629 (1985).
2. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch. Intern. Med. 160(4), 501-509 (2000).
3. Gaynes R, Edwards JR. Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis. 41(6), 848-854 (2005).
4. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32(8), 470-485 (2004).
5. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 48(12), 4606-4610 (2004).
6. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol. 55(Pt 12), 1619-1629 (2006).
7. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2), S146-S155 (2001).
8. Tam VH, Chang KT, Abdelraouf K, et al. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54(3), 1160-1164 (2010).
9. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48(12), 1724-1728 (2009).
10. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int. J. Antimicrob. Agents 34(5), 434-438 (2009).
11. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 10(1), R27 (2006).
12. Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin. Infect. Dis. 48(6), 713-721 (2009).
13. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60(6), 1206-1215 (2007).
14. Yuan Z, Tam VH. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin. Investig. Drugs 17(5), 661-668 (2008).
15. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6(9), 589-601 (2006).
16. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34(5), 634-640 (2002).
17. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43(Suppl. 2), S49-S56 (2006).
18. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 64(2), 159-204 (2004).
19. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs 69(12), 1555-1623 (2009).
20. Li XZ, Barre N, Poole K. Influence of the MexA-MexB-oprM multidrug efflux system on expression of the MexC-MexD-oprJ and MexE-MexF-oprN multidrug efflux systems in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 46(6), 885-893 (2000). (Pubitemid 32000597)
21. Poole K. Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect. 10(1), 12-26 (2004).
22. Kotra LP, Haddad J, Mobashery S. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob. Agents Chemother. 44(12), 3249-3256 (2000).
23. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis. 45(1), 88-94 (2007).
24. Doi Y, Wachino J, Arakawa Y. Nomenclature of plasmid-mediated 16S rRNA methylases responsible for panaminoglycoside resistance. Antimicrob. Agents Chemother. 52(6), 2287-2288 (2008).
25. Galimand M, Sabtcheva S, Courvalin P, Lambert T. Worldwide disseminated armA aminoglycoside resistance methylase gene is borne by composite transposon Tn1548. Antimicrob. Agents Chemother. 49(7), 2949-2953 (2005).
26. Yamane K, Wachino J, Doi Y, Kurokawa H, Arakawa Y. Global spread of multiple aminoglycoside resistance genes. Emerg. Infect. Dis. 11(6), 951-953 (2005).
27. Tam VH, Schilling AN, LaRocco MT, et al. Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin. Microbiol. Infect. 13(4), 413-418 (2007).
28. Jalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 44(3), 710-712 (2000).
29. Andersson DI. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol. 9(5), 461-465 (2006).
30. Ramadhan AA, Hegedus E. Survivability of vancomycin resistant enterococci and fitness cost of vancomycin resistance acquisition. J. Clin. Pathol. 58(7), 744-746 (2005).
31. Criswell D, Tobiason VL, Lodmell JS, Samuels DS. Mutations conferring aminoglycoside and spectinomycin resistance in Borrelia burgdorferi. Antimicrob. Agents Chemother. 50(2), 445-452 (2006).
32. Deptula A, Gospodarek E. Reduced expression of virulence factors in multidrug-resistant Pseudomonas aeruginosa strains. Arch. Microbiol. 192(1), 79-84 (2009).
33. Sanchez P, Linares JF, Ruiz-Diez B, et al. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J. Antimicrob. Chemother. 50(5), 657-664 (2002).
34. Ohmagari N, Hanna H, Graviss L, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 104(1), 205-212 (2005).
35. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 50(1), 43-48 (2006).
36. Paramythiotou E, Lucet JC, Timsit JF, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin. Infect. Dis. 38(5), 670-677 (2004).
37. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J. Hosp. Infect. 57(2), 112-118 (2004).
38. Arruda EA, Marinho IS, Boulos M, et al. Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect. Control Hosp. Epidemiol. 20(9), 620-623 (1999).
39. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136(5), 1237-1248 (2009).
40. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34(6), 1589-1596 (2006).
41. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob. Agents Chemother. 49(2), 760-766 (2005).
42. Fraser A, Paul M, Almanasreh N, et al. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am. J. Med. 119(11), 970-976 (2006).
43. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J. Intern. Med. 244(5), 379-386 (1998).
44. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin. Infect. Dis. 47(Suppl. 1), S3-S13 (2008).
45. Bassetti M, Righi E, Viscoli C. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy? Curr. Med. Chem. 15(5), 517-522 (2008).
46. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. 37(6), 745-751 (2003).
47. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother. 49(4), 1306-1311 (2005).
48. Osih RB, McGregor JC, Rich SE, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 51(3), 839-844 (2007).
49. Lodise TP Jr, Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob. Agents Chemother. 51(10), 3510-3515 (2007).
50. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch. Intern. Med. 156(18), 2121-2126 (1996).
51. Yuan Z, Ledesma KR, Singh R, Hou J, Prince RA, Tam VH. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J. Infect. Dis. 201(6), 889-897 (2010).
52. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47(9), 2756-2764 (2003).
53. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis. 4(8), 519-527 (2004).
54. Paul M, Leibovici L. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect. Dis. Clin. North Am. 23(2), 277-293 (2009).
55. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. b lactam antibiotic monotherapy versus b lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst. Rev. (1), CD003344 (2006).
56. Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am. J. Med. 119(6), 526 e519-525 (2006).
57. Laupland KB, Parkins MD, Church DL, et al. Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-b-lactamase (MBL)-producing strains. J. Infect. Dis. 192(9), 1606-1612 (2005).
58. Queenan AM, Bush K. Carbapenemases: the versatile b-lactamases. Clin Microbiol Rev, 20(3), 440-458 (2007).
59. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 27(9), 893-900 (2006).
60. Lautenbach E, Synnestvedt M, Weiner MG, et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 31(1), 47-53 (2010).
61. Hirakata Y, Yamaguchi T, Nakano M, et al. Clinical and bacteriological characteristics of IMP-type metallo-b-lactamase-producing Pseudomonas aeruginosa. Clin. Infect. Dis. 37(1), 26-32 (2003).
62. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. 36(11), 1433-1437 (2003).
63. Tam VH, Chang KT, Schilling AN, LaRocco MT, Genty LO, Garey KW. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn. Microbiol. Infect. Dis. 63(3), 279-285 (2009).
64. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch. Intern. Med. 159(10), 1127-1132 (1999).
65. Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am. J. Infect. Control 33(9), 501-509 (2005).
66. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48(1), 1-12 (2009).
67. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin. Infect. Dis. 49(8), 1175-1184 (2009).
68. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant Gram-negative bacteria. Antimicrob. Agents Chemother. 54(1), 109-115 (2010).
69. Evans HL, Lefrak SN, Lyman J, et al. Cost of Gram-negative resistance. Crit. Care Med. 35(1), 89-95 (2007).
70. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch. Intern. Med. 162(2), 185-190 (2002).
71. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-b-lactamase- producing Enterobacteriaceae. Antimicrob. Agents Chemother. 50(4), 1257-1262 (2006).
72. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin. Infect. Dis. 28(5), 1128-1133 (1999).
73. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289(7), 885-888 (2003).